Jonathan Aschoff

In a report published Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Medivation, Inc. (NASDAQ: MDVN), and raised the price target from $125.00 to $142.00. In the report, Brean Capital noted, "At the European Association of Urology Congress yesterday, two abstracts were...

In a report published Friday, Brean Capital analyst Jonathan Aschoff said that that Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) is a "prime takeout candidate" as the company continues to target NDA submission for eravacycline for both indications (cUTI and cIAI) by the end of 2015...

Brean Capital reiterated its Sell rating on Rockwell Medical Inc (NASDAQ: RMTI) on Monday following the FDA approval of its Triferic iron replacement product. The firm maintained a $4 price target. Analysts Jonathan Aschoff and Yi Cheng expected “dismal commercial uptake” for the...

In a report published Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Chimerix Inc (NASDAQ: CMRX), and raised the price target from $33.00 to $45.00. In the report, Brean Capital noted, “The Phase 3 SUPPRESS and AdVise trials with brincidofovir are well underway, and we...

After an eventful 2014, the Brean Capital team came together to pick 28 stocks within each of the firm’s four coverage verticals -- Consumer, Healthcare, Natural Resources, and Technology -- to pay attention to in 2015. Below are four of the highlighted stocks, with one from each vertical...

In a report published Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $390.00 to $450.00. In the report, Brean Capital noted, “At the AHA meeting, positive results from six of the several ongoing...

In a report published Tuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and $41.00 price target on Repros Therapeutics (NASDAQ: RPRX). In the report, Brean Capital noted, “Following the constructive FDA guidance meeting held last Wednesday, Repros will promptly set up a call...

In a report published Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Nektar Therapeutics (NASDAQ: NKTR), but lowered the price target from $17.00 to $14.00. In the report, Brean Capital noted, “Nektar missed the primary endpoint in its Phase 2 trial with NKTR-181 in...